28 articles about Kriya Therapeutics
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy.
Kriya Therapeutics, Inc., (Kriya) today announced its gene therapy program for thyroid eye disease (TED), a debilitating autoimmune condition resulting in proptosis and diplopia, medical terms describing bulging of the eyes and double vision respectively, due to inflammation of the muscles and fat tissue behind the eye.
Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy
Kriya Therapeutics, Inc. ("Kriya") has entered into an exclusive license, collaboration and supply agreement with Everads Therapy, Ltd (“Everads”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads' suprachoroidal delivery device.
Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases
Kriya Therapeutics, Inc. today announced that it has acquired Tramontane Therapeutics, Inc. ("Tramontane").
Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases
Kriya Therapeutics, Inc. today announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to over $430 million.
Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced that it will present 10 abstracts at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place in Los Angeles, CA, May 16-20, 2023.
In the acquisition, announced Wednesday, Kriya picks up two gene therapy programs focused on epilepsy and trigeminal neuralgia. Financial terms of the deal were not disclosed.
Kriya Therapeutics, Inc. today announced the acquisition of Redpin Therapeutics, Inc., a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.
Kriya Therapeutics, Inc. announced today that it has appointed Curt Herberts, M.B.S., as President and Chief Operating Officer. Herberts will oversee all general and administrative functions at Kriya.
Kriya Therapeutics, Inc announced today that it has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division.
Kriya Therapeutics tapped longtime pharma veteran Pedro Huertas as chief medical officer of its rare disease division.
Kriya Therapeutics, Inc., a fully integrated gene therapy company pioneering novel technologies and therapeutics, announced a $270 Million Series C financing.
Kriya Therapeutics secured $270 million that will be used to advance its fully integrated gene therapy pipeline and expand engineering, manufacturing and computation.
Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy
Twist Bioscience Corporation and Kriya Therapeutics, Inc. today announced an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications.
Kriya forged an antibody discovery agreement with Twist to support the delivery of antibodies with AAV gene therapy in therapeutic oncology applications.
2/11/2022Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Kriya Announces the Appointment of Ma’an Muhsin, M.D., as President and Chief Medical Officer of Its Oncology Therapeutic Area Division
Kriya Therapeutics, Inc. announced today that it has appointed Ma’an Muhsin, M.D., as President and Chief Medical Officer of Kriya Oncology.
Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases
Kriya Therapeutics, Inc. today announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.
Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division With the Acquisition of Warden Bio
Kriya Therapeutics, Inc. announced today that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs).
Kriya Therapeutics Expands Leadership Team with the Appointment of Neera Ravindran, M.D., M.B.A. as Chief Financial Officer
Kriya Therapeutics, Inc. today announced the appointment of Neera Ravindran, M.D., M.B.A., as Chief Financial Officer.